Doctors are raising concerns that widely used weight-loss medications, including Ozempic and Wegovy, may not be appropriate for everyone with certain neurological conditions. The warning centers on people with neurodegenerative diseases such as ALS, where unintended or rapid weight loss can be especially harmful.
According to neurologists, body weight can play an important role in how ALS progresses. For some patients, losing weight may speed up the course of the disease, making the appetite-reducing effects of these drugs a potential problem rather than a benefit.
Specialists say the issue highlights the need for careful medical oversight before prescribing weight-loss treatment to people with complex underlying conditions. While these medications have helped many patients manage obesity and related health problems, experts caution that the same approach may carry added risks in people whose illness is affected by nutrition and muscle loss.
The warning does not suggest the drugs are unsafe for all users, but it underscores that treatment decisions should account for a patient’s full medical picture. In people with ALS or similar disorders, doctors may need to weigh any potential metabolic benefits against the dangers linked to further weight reduction.
